PhosphoPlus^® Ezh2 (Thr345) Antibody Duet #80780

The polycomb group (PcG) proteins are involved in maintaining the silenced state of several developmentally regulated genes and contribute to the maintenance of cell identity, cell cycle regulation, and oncogenesis (1,2). Enhancer of zeste homolog 2 (Ezh2), a member of this large protein family, contains four conserved regions including domain I, domain II, and a cysteine-rich amino acid stretch that precedes the carboxy-terminal SET domain (3). The SET domain has been linked with histone methyltransferase (HMTase) activity. Moreover, mammalian Ezh2 is a member of a histone deacetylase complex that functions in gene silencing, acting at the level of chromatin structure (4). Ezh2 complexes methylate histone H3 at Lys9 and 27 in vitro, which is thought to be involved in targeting transcriptional regulators to specific loci (5). Ezh2 is deregulated in various tumor types, and its role, both as a primary effector and as a mediator of tumorigenesis, has become a subject of increased interest (6).

Ezh2 was shown to be phosphorylated by cyclin-dependent kinase 1 (CDK1) at Thr345 and Thr487 in a cell cycle-dependent manner (7). It has also been shown that the ANCR long non-coding RNA potentiates the Ezh2-CDK1 interaction, leading to increased phosphorylation of Thr345 and Thr487 on Ezh2 and facilitating ubiquitination and subsequent degradation of this protein (8).